When the right nutrition and hydration strategies are in place, most people see significant improvement
Some patients continue GLP-1 therapy long-term at a maintenance dose to support sustained weight loss
Evidence from the SURPASS phase III clinical trial program has consistently demonstrated the superior metabolic efficacy of tirzepatide compared with currently available GLP-1 receptor agonists, such as semaglutide
Essential oils can counteract edema formation by reducing elevated levels of arachidonic acid derivatives, such as prostaglandins and leukotrienes, thus demonstrating their potential to modulate inflammatory responses
statistically significant improvement in motor symptoms Another trial with once-daily self-administered injections of liraglutide (1.2 or 1.8 mg, as tolerated) or placebo in 62 patients with PD reported improvements in MDS-UPDRS-2 (an activity of daily living scale), but not in MDS-UPDRS-3, in treated patients vs placebo